If you have spent time in injury-recovery or peptide circles, you have probably heard of TB-500. It is a synthetic peptide based on thymosin beta-4, a protein found in nearly every human cell that helps cells move into damaged tissue and repair it. TB-500 is not FDA approved, but it has become one of the most discussed peptides for soft-tissue recovery, often alongside BPC-157.
This beginner's guide covers what TB-500 is, how it works, its potential benefits, the dosing protocols that circulate, what is known about pairing it with BPC-157, side effects, legal status and drug testing.
What Is TB-500?
Thymosin beta-4 (Tβ4) is a 43-amino-acid protein that is especially abundant in platelets and white blood cells, which are among the first cells to arrive at an injury. Its main known job is binding actin, the protein that forms the internal skeleton cells use to move and change shape.
TB-500 is a synthetic peptide built from the part of Tβ4 that binds actin. The FDA defines it as the seven-amino-acid fragment LKKTETQ (Leu-Lys-Lys-Thr-Glu-Thr-Gln), which corresponds to amino acids 17–23 of the full protein. Labeling is inconsistent, though, and some products sold as TB-500 contain full-length Tβ4.
That distinction matters. Almost all human research was done on full-length Tβ4. The TB-500 fragment itself has no published human trials.
How TB-500 Works
Research on thymosin beta-4 points to several actions:
-
Actin binding and cell migration: by holding onto G-actin, the building block of the cell skeleton, Tβ4 helps control how cells reshape themselves. That lets repair cells move into a wound more efficiently.
-
Blood vessel growth: promotes angiogenesis, bringing more blood, oxygen and immune cells to damaged tissue.
-
Inflammation: reduces inflammatory signaling in several animal models.
-
Scarring: a smaller Tβ4 fragment, Ac-SDKP, has shown anti-fibrotic effects, which could mean less scar tissue.
TB-500 is often described as working "systemically," circulating through the body rather than acting at one spot. That idea comes from how Tβ4 behaves, not from studies of the fragment in people.
Potential Benefits of TB-500
The benefits below are based mostly on research with full-length Tβ4, in animals or in human trials of specific formulations.
Muscle, Tendon and Ligament Healing
This is TB-500's main draw. Tβ4's role in cell migration and blood vessel growth is the proposed basis for faster soft-tissue repair. Controlled human trials in sports injuries have not been done.
Wound Healing
In animals, Tβ4 sped up wound closure. In humans, a topical Tβ4 gel (RGN-137) showed Phase 2 signals of faster healing in chronic skin wounds.
Eye Surface Repair
The strongest human evidence comes from Tβ4 eye drops (RGN-259). Phase 3 trials in dry eye, with about 1,500 patients pooled, and in neurotrophic keratopathy reported improvements and a consistent safety record.
Inflammation
Animal studies show reduced inflammation, which is part of why TB-500 is discussed for tendonitis and other inflammatory injuries.
Heart and Nerve Repair
Rodent studies report better recovery after heart attack and protective effects after brain and spinal injury. These remain animal findings.
TB-500 and BPC-157
TB-500 and BPC-157 are the most commonly paired recovery peptides.
Why They Are Paired
| TB-500 | BPC-157 | |
|---|---|---|
| Main proposed action | Cell migration via actin binding | Blood vessel growth, nitric oxide system, tendon cell activity |
| Often described as | Systemic | Local |
| Length | 7 amino acids | 15 amino acids |
| Human data | None for the fragment; Phase 3 for Tβ4 eye drops | 3 small pilot studies |
The reasoning is that the two act through different pathways, so they might complement each other. Online protocols typically run both at the same time, layering their individual schedules.
What the Evidence Says
The only human data on the combination is a small retrospective study of knee pain in which some patients received BPC-157 with thymosin beta-4. It was not controlled. No trial has tested whether the pairing works better than either peptide alone, or whether it is safe.
Side Effects and Safety
Reported Side Effects
Mostly from user reports:
-
Injection-site redness, swelling or discomfort
-
Tiredness or lethargy
-
Mild headache or dizziness
-
Flushing or lightheadedness after injection
Full-length Tβ4 trials, including eye drops and IV dosing, reported a favorable safety profile. There is no human safety data for the TB-500 fragment.
Tumor Concern
Because Tβ4 promotes cell migration and blood vessel growth, researchers have raised a theoretical concern about effects on existing tumors. Some studies link high Tβ4 levels to cancer progression, though that is not proof that taking it causes harm. People with a history of cancer should avoid it.
Product Quality
Research-grade products can vary in purity, sterility and whether they contain the fragment or the full protein. Contaminants such as bacterial endotoxins can cause reactions.
Who Should Avoid It
-
People with a history of cancer
-
People who are pregnant or breastfeeding
-
Competitive athletes subject to drug testing
Legal Status and Drug Testing
United States
-
TB-500 is not approved by the FDA and is not a controlled substance.
-
2023: placed on the FDA's Category 2 list, blocking compounding.
-
April 2026: removed from Category 2 after its nomination was withdrawn.
-
July 23, 2026: the FDA's compounding advisory committee voted 8–6, with one abstention, to recommend adding TB-500 to the list compounding pharmacies may use, for wound healing.
-
The vote is advisory. Compounding is not permitted until the FDA completes formal rulemaking.
Anti-Doping
Thymosin beta-4 and its derivatives, including TB-500, are named on the World Anti-Doping Code's prohibited list under peptide hormones and growth factors. They are banned in and out of competition, and TB-500 can be detected in testing.
Elsewhere
TB-500 is not approved as a medicine in other major markets. Rules on import and sale of research peptides vary by country.
Conclusion: What Beginners Should Know
TB-500 is built on a protein with a clear role in tissue repair. Thymosin beta-4 helps cells move into injuries and supports blood vessel growth, and it has reached Phase 3 trials as an eye drop. That is a stronger biological foundation than many research peptides have.
The catch is that the evidence is mostly for the full protein in specific formulations, not for the TB-500 fragment injected for sports injuries. Dosing protocols come from user communities rather than trials, and the popular pairing with BPC-157 is untested.
Key points:
-
Its proposed benefits center on soft-tissue repair, wound healing and inflammation.
-
Circulating protocols use a loading phase and a maintenance phase.
-
It is banned for tested athletes.
-
People with a history of cancer should avoid it.
TB-500 FAQ
How long does TB-500 take to work?
There is no human trial data for the fragment. User reports often describe changes within a few weeks, but those reports are not controlled.
Can TB-500 be used without BPC-157?
Yes. They are separate compounds, and pairing them is a community practice, not a tested protocol.
Is TB-500 safe long term?
Long-term human safety data does not exist for the fragment. The theoretical tumor concern is a key reason for caution with extended use.
Does TB-500 build muscle?
No. It is not anabolic and does not raise testosterone or growth hormone. Its proposed effects are on repair and recovery.
Is TB-500 legal?
It is not FDA approved. An FDA advisory committee recommended it for compounding in July 2026, but compounding is not allowed until the FDA finalizes that through rulemaking.
Can TB-500 be detected in a drug test?
Yes. It is prohibited by WADA and can be detected in anti-doping testing.
Disclaimer
This article is for educational and informational purposes only. TB-500 is not approved by the FDA or any regulatory body. Dosing information describes published research and protocols circulating online and is not a recommendation for use. Nothing here is medical advice. The Peptide Library is operated in connection with ZenoPeps. Research products are not intended for human consumption.
References
-
Goldstein AL, Hannappel E, et al. Thymosin β4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy, 2012.
-
Malinda KM, et al. Thymosin β4 accelerates wound healing. Journal of Investigative Dermatology, 1999.
-
Thymosin beta 4 ophthalmic solution for dry eye: Phase II trial, Clinical Ophthalmology, 2015.
-
ARISE-3 and pooled dry eye results, RegeneRx.
-
FDA advisory committee vote coverage, July 2026.